A.R.T. Advisors’s Impax Laboratories, Inc. IPXL Stock Holding History

A.R.T. Advisors’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-65,624	Closed	-$1.06M	–	1883
2017 Q2	$1.06M	Sell	65,624 -147,665	-69%	-$2.18M	0.06%	499
2017 Q1	$2.7M	Buy	+213,289	New	+$2.58M	0.12%	220
2016 Q4	–	Sell	-15,000	Closed	-$355K	–	1467
2016 Q3	$355K	Sell	15,000 -43,259	-74%	-$1.16M	0.11%	283
2016 Q2	$1.68M	Buy	58,259 +40,775	+233%	+$1.33M	0.08%	368
2016 Q1	$559K	Buy	17,484 +1,700	+11%	+$59.8K	0.03%	815
2015 Q4	$674K	Sell	15,784 -15,087	-49%	-$603K	0.03%	732
2015 Q3	$1.09M	Buy	30,871 +21,885	+244%	+$986K	0.04%	600
2015 Q2	$412K	Buy	+8,986	New	+$427K	0.01%	1066
2014 Q4	–	Sell	-41,278	Closed	-$978K	–	1807
2014 Q3	$978K	Buy	+41,278	New	+$1.06M	0.05%	510
2013 Q4	–	Sell	-116,165	Closed	-$2.38M	–	1670
2013 Q3	$2.38M	Buy	116,165 +77,266	+199%	+$1.6M	0.13%	229
2013 Q2	$775K	Buy	+38,899	New	+$690K	0.03%	716

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

A.R.T. Advisors's IPXL Position: Q3 2017 in Review

A.R.T. Advisors sold out of Impax Laboratories, Inc. (IPXL) in Q3 2017, closing a stake of 65,624 shares — an estimated $1.06M sold.

A.R.T. Advisors first reported a position in IPXL in Q2 2013 and held it in 11 quarters. The position peaked at $2.7M in Q1 2017. 189 funds tracked by Wall St. Rank hold IPXL as of Q3 2017.

A.R.T. Advisors reported no remaining Impax Laboratories, Inc. position as of Q3 2017 after selling out during the quarter.
A.R.T. Advisors sold 65,624 Impax Laboratories, Inc. shares in Q3 2017, an estimated $1.06M.
A.R.T. Advisors first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 11 quarters.
A.R.T. Advisors's Impax Laboratories, Inc. position peaked at $2.7M in Q1 2017.
189 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2017.

Based on A.R.T. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.